Minase Research Institute, Ono Pharmaceutical Co., Ltd., Shimamoto, Mishima, Osaka 618-8585, Japan.
Bioorg Med Chem. 2012 Apr 1;20(7):2235-51. doi: 10.1016/j.bmc.2012.02.018. Epub 2012 Feb 16.
To identify potent EP2/EP4 dual agonists with excellent subtype selectivity, a series of γ-lactam prostaglandin E analogs bearing a 16-phenyl ω-chain were synthesized and evaluated. Structural hybridization of 1 and 2, followed by more detailed chemical modification of the benzoic acid moiety, led us to the discovery of a 2-mercaptothiazole-4-carboxylic acid analog 3 as the optimal compound in the series. An isomer of this compound, the 2-mercaptothiazole-5-carboxylic acid analog 13, showed 34-fold and 13-fold less potent EP2 and EP4 receptor affinities, respectively. Structure activity relationship data from an in vitro mouse receptor binding assay are presented. Continued evaluation in an in vivo rat model of another 2-mercaptothiazole-4-carboxylic acid analog 17, optimized for sustained compound release from PLGA microspheres, demonstrated its effectiveness in a rat bone fracture-healing model following topical administration.
为了寻找具有良好亚型选择性的强效 EP2/EP4 双重激动剂,我们合成并评价了一系列带有 16-苯基 ω-链的γ-内酰胺前列腺素 E 类似物。通过对苯甲酸部分进行更详细的化学修饰,对 1 和 2 进行结构杂交,使我们发现了 2-巯基噻唑-4-羧酸类似物 3 是该系列中的最佳化合物。该化合物的异构体,2-巯基噻唑-5-羧酸类似物 13,对 EP2 和 EP4 受体的亲和力分别降低了 34 倍和 13 倍。呈现了来自体外小鼠受体结合测定的结构活性关系数据。对另一种 2-巯基噻唑-4-羧酸类似物 17 的体内大鼠模型的持续评估,该化合物经过 PLGA 微球的持续化合物释放进行了优化,在大鼠骨折愈合模型中证明了其经皮给药的有效性。